These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15100150)

  • 1. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation.
    Imado T; Iwasaki T; Kataoka Y; Kuroiwa T; Hara H; Fujimoto J; Sano H
    Blood; 2004 Sep; 104(5):1542-9. PubMed ID: 15100150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice].
    Xia YJ; Gao QP; Wan CC; Cheng FJ; Liu ZX; Guo RC
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):404-7. PubMed ID: 16251021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
    Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
    Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
    Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
    Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
    Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
    Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation.
    van der Straaten HM; Fijnheer R; Dekker AW; Nieuwenhuis HK; Verdonck LF
    Br J Haematol; 2001 Jul; 114(1):31-5. PubMed ID: 11472341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
    Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
    Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.
    Alpdogan O; Eng JM; Muriglan SJ; Willis LM; Hubbard VM; Tjoe KH; Terwey TH; Kochman A; van den Brink MR
    Blood; 2005 Jan; 105(2):865-73. PubMed ID: 15280205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
    Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
    J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
    Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse embryonic stem cell-derived thymic epithelial cell progenitors enhance T-cell reconstitution after allogeneic bone marrow transplantation.
    Lai L; Cui C; Jin J; Hao Z; Zheng Q; Ying M; Boyd R; Zhao Y
    Blood; 2011 Sep; 118(12):3410-8. PubMed ID: 21791423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
    Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
    Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flt-3L Expansion of Recipient CD8α
    Markey KA; Kuns RD; Browne DJ; Gartlan KH; Robb RJ; Martins JP; Henden AS; Minnie SA; Cheong M; Koyama M; Smyth MJ; Steptoe RJ; Belz GT; Brocker T; Degli-Esposti MA; Lane SW; Hill GR
    Clin Cancer Res; 2018 Apr; 24(7):1604-1616. PubMed ID: 29367429
    [No Abstract]   [Full Text] [Related]  

  • 20. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
    Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
    Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.